Jagsonpal Pharmaceuticals has informed that consequent to the appointment of Nirav Niranjankumar Vora as Chief Financial Officer, the Board of Directors have approved changes in KMPs authorized for the purpose of determining the materiality of an event or information and for the purpose of making disclosures to stock exchange(s) under the SEBI (LODR). The contact details of the KMPs authorized are as enclosed.
The above information is a part of company’s filings submitted to BSE.
